MediPoint: Breast Cancer Imaging - EU Analysis and Market Forecasts

Reportstack has announced a new market report on MediPoint: Breast Cancer Imaging - EU Analysis and Market Forecasts. Breast cancer is the most common form of cancer in women in both the developed and developing world, but is a rare disease in men. The global incidence of breast cancer is increasing due to an increased lifespan and increasing adoption of western lifestyle risk factors. Early diagnosis of breast cancer is the foundation for increasing survival rates and diagnostic imaging is the most widely used technique to achieve early detection, making diagnostic imaging a cornerstone of breast cancer control.

The EU breast cancer imaging market is a mature industry with complex dynamics. The dynamics of this industry vary greatly from one country to another. Therefore, it is essential to examine the market opportunities and barriers that are specific to each region. This report provides an in-depth review of the evolving technologies and the regulatory landscape in the breast cancer screening markets in the EU countries.

Scope

- An overview of breast cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU Breast cancer imaging market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for Breast cancer imaging
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the Breast cancer imaging sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as radiologists

Reasons to buy

- Understand the trends shaping and driving the EU Breast cancer imaging Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the EU Breast cancer imaging Market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What’s the next big thing in EU Breast cancer imaging market landscape? Identify, understand and capitalize.

The Companies Mentioned in this report are GE Healthcare Hologic Siemens Koninklijke Philips Electronics Fujifilm Medical Systems Internazionale Medico Scientifica (IMS) Planmed Konica Minolta Medical Imaging Agfa Healthcare Carestream Health SonoCine Aurora Imaging Technology Imaging Diagnostic Systems Naviscan Dilon Diagnostics Gamma Medica Allengers Medical Systems.

To view the table of contents and know more details please visit MediPoint: Breast Cancer Imaging - EU Analysis and Market Forecasts report.

Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Reportstack has announced a new market report on Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.

Faldaprevir is a direct-acting antiviral being developed by the German company BI for the treatment of HCV infection. Faldaprevir, previously referred to as BI 201335 or BI 1335, is an NS3/4A protease inhibitor (PI) that is currently in Phase III development.

Scope

- Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Faldaprevir and BI 207127 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Faldaprevir and BI 207127 for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Faldaprevir and BI 207127 performance
- Obtain sales forecast for Faldaprevir and BI 207127 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China).

To view the table of contents and know more details please visit Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 report.

Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Reportstack has announced a new market report on Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.

Daclatasvir is a DAA being developed by BMS for the treatment of HCV infection. The mechanism of action of daclatasvir involves the inhibition the NS5A protein. NS5A is unique to HCV, and the protein is essential for multiple functions in the viral lifecycle, including HCV RNA replication, despite not having any enzymatic activity.

Scope

- Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Daclatasvir, Asunaprevir, and Peginterferon Lambda including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Daclatasvir, Asunaprevir, and Peginterferon Lambda for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Daclatasvir, Asunaprevir, and Peginterferon Lambda performance
- Obtain sales forecast for Daclatasvir, Asunaprevir, and Peginterferon Lambda from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China).

To view the table of contents and know more details please visit Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022 report.

AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Reportstack has announced a new market report on AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) - Forecast and Market Analysis to 2022. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.

AbbVie is developing an interferon-free HCV regimen that is a combination of the following three or four drugs: ABT-450 is an inhibitor of the HCV protease. This enzyme is required for viral polyprotein processing, which makes the protease essential for HCV replication (Asselah and Marcellin, 2013). Inhibitors of the HCV protease are, therefore, attractive antiviral drugs. ABT-450 is boosted with ritonavir. 

ABT-267 is an inhibitor of the HCV NS5A protein, which is unique to HCV. The protein is essential for multiple functions in the viral lifecycle, including HCV RNA replication, despite not having any enzymatic activity (Hunt and Pockros, 2013). NS5A is, therefore, an attractive antiviral drug target. ABT-333 is an NS5B nucleotide polymerase inhibitor. ABT-333 exhorts its antiviral activity by mimicking the natural substrate of the viral RNA-dependent RNA polymerase.

Scope

- Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on ABT-450, ABT-333, and ABT-267 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for ABT-450, ABT-333, and ABT-267 for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of ABT-450, ABT-333, and ABT-267 performance
- Obtain sales forecast for ABT-450, ABT-333, and ABT-267 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China).

To view the table of contents and know more details please visit AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 report.

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Reportstack has announced a new market report on China Large Volume Parenteral (LVP) Industry Report, 2013-2015. Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China’s injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.

Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.

Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.

Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.

Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.

The report highlights the followings:

- Status quo, competition patterns, product structure, regional distribution and development forecast of Chinese LVP market;
- Status quo and competition patterns of fluid balance injection, therapeutic injection, nutrition injection, injection for blood volume expansion and peritoneal dialysis fluid injection and other market segments;
- Operation, LVP business and prospects of 10 companies including Kelun Pharma, China Resources Double-Crane, Fengyuan Pharmaceutical, Huaren Pharmaceutical, Southwest Pharmaceutical and Lijun International Pharmaceutical.

To view the table of contents and know more details please visit China Large Volume Parenteral (LVP) Industry Report, 2013-2015.

Global and China Laser Equipment and Processing Industry Report, 2013-2017

Reportstack has announced a new market research publication on Global and China Laser Equipment and Processing Industry Report, 2013-2017. The European and American economic crisis, Asian economic slowdown and a number of other factors have impacted the development of global laser industry, and reduced the growth rate of global industrial laser sector to single digit. The growth rate of global laser system market declined from 16% in 2011 to 6% in 2012, and is expected to further drop to around 4% in 2013.

As a global processing and manufacturing center, China has continuously expanded the installation of laser processing equipment and occupied more than 10% of the global market. However, due to the weak downstream demand, the growth rate of Chinese laser equipment market in 2012 and 2013 both fell to below 10%. Among major enterprises, only Han’s Laser Technology and Shenzhen Sunshine Laser and Electronics Technology have achieved business growth, other enterprises have realized a little growth or negative growth. With continuous upgrading of processing and manufacturing industry, it’s expected that the laser industry will see recovery growth and business performance will pick up in 2014 and 2015.

Han’s Laser Technology is China’s largest laser equipment manufacturer with the most complete products. Despite the laser industry downturn, Han’s Laser Technology has maintained rapid growth, and achieved a year-on-year revenue growth rate of 18.53% in the first half of 2013. In particular, the revenue from high-power laser cutting equipment, laser welding equipment and laser cutting equipment rose by 77.13%, 13.32% and 35.03% year on year respectively.

Shenzhen Sunshine Laser and Electronics Technology is China’s largest laser processing service company with the most complete business types. It occupies big shares in the laser template processing and laser forming service markets, which are expected to hit 21% and 13% respectively in 2013. In the first half of 2013, the growth rate of its revenue from laser forming services, HDI drilling and UV drilling reached 41.63%, 119.33% and 575.08% respectively, displaying strong growth momentum.

Global and China Laser Equipment and Processing Industry Report, 2013-2017  mainly includes the following:

- Sales, major enterprises, application fields, market segments and forecast of global laser industry;
- Market size, major enterprises, regional distribution, import & export and forecast of laser equipment in China;
- Market development and forecast of laser cutting equipment, laser marking equipment, laser welding equipment, laser engraving equipment, laser medical equipment and laser holography in China;
- Development of Chinese laser processing industry as well as market and forecast of laser template, precision metal parts, laser forming and laser drilling businesses;
- Business development of major laser processing equipment manufacturers in China and worldwide. 

To view the table of contents and know more details please visit Global and China Laser Equipment and Processing Industry Report, 2013-2017.

Global and China Financial POS Terminal Industry Report,2013-2016

Reportstack has announced a new market research publication on Global and China Financial POS Terminal Industry Report,2013-2016. POS (point-of-sale) machine is used for sales information collection and capital, merchandise balance recording of points of sale, associated with the settlement system of trading platform. Currently, it is mainly available for appointed merchants accepting bankcard consumption, known as the “financial POS terminal”.

Global POS terminal shipments reached 19.41 million units in 2012, a year-on-year increase of 17.42%, with a CAGR of 10.20% in 2007-2012, of which, Asia, Latin America and EMEA (Europe, Middle East and Africa) regions occupied the top three positions by CAGR of shipment, respectively 25.46%, 16.39% and 15.41%, respectively.

In 2007-2012 the number of POS machines joined the UnionPay network in China rose from 1,181,200 units to 7,117,800 units at a CAGR of 43.22%. During the corresponding period, the number of new POS machines joined the UnionPay network went up from 363,200 units to 2,291,300 units at a CAGR of 44.54%.

In 2012 shipments of China’s top ten POS terminal enterprises totaled up to 6,104,410 units, accounting for 31.44% of the global POS terminal shipments, of which, Fujian Landi Commercial Equipment Co., Ltd., PAX Global Technology Limited and Shenzhen Xinguodu Technology Co., Ltd. were the top three.

By market segment, handheld mobile POS machines and NFC-enabled mobile phone POS machines grow faster.

With the maturity of operation and other aspects of payment platform as well as the improvement of mobile payment environment in China, the number of handheld mobile POS machines configured in e-commerce, express industry, public utilities (water, electricity and gas) will maintain rapid growth. Meanwhile, affected by the fast-growing shipments of NFC-enabled smart phones, the number of NFC-enabled POS machines will increase significantly.

Global and China Financial POS Terminal Industry Report, 2013-2016 mainly covers the followings:
- Global financial POS machine market (including bankcard consumer transactions, enterprise POS terminal shipments, etc. of global market, market segments and regional markets);
- China’s financial POS machine market (including market overview, market size, competition pattern, market segments, etc.);
- China’s bankcard payment market (including bankcard issuance volume, consumption, interbank payment and financial IC card, etc.);
- China’s major financial POS machine deployment and acquirers (including acquiring market situation, features as well as bankcard business, trends and prospects of UnionPay and China’s four major state-owned commercial banks);
- Operating conditions of global and Chinese financial POS machine manufacturing enterprises (including revenue, net income, revenue structure, gross margin, R&D spending, strategic planning, development prospects, etc.). 

To view the table of contents and know more details please visit Global and China Financial POS Terminal Industry Report,2013-2016.